Journal: Agronomy

Article Title: Cowpea: Prospecting for Heat-Tolerant Genotypes

doi: 10.3390/agronomy14091969

Figure Lengend Snippet: Figure 1. Genetic variability of seed morphology and size of studied cowpea genotypes. GN1: BRS Inhuma; GN2: Bico-de-Ouro-17-10; GN3: Pingo-de-Ouro-17-18; GN4: Bico-de-Oouro-17-19; GN5: Bico-de-Ouro-17-20; GN6: Bico-de-Ouro-17-44; GN7: Bico-de-Ouro-17-45; GN8: Bico-de-Ouro-17-46; GN9: Bico-de-Ouro-17-47; GN10: Pingo-de-Ouro-17-48; GN11: Bico-de-Ouro-17-72; G12: BRS Guariba; GN13: Bico-de-Ouro-17-82; GN14: Bico-de-Ouro-17-86; GN15: MNC01-631F-20-5; GN16: MNC00-595F-27; GN17: BRS Imponente; GN18: MNC06-895E-1; GN19: MNC09-981B-2; GN20: BRS Paraguaçu.

Article Snippet: GN1: BRS Inhuma; GN2: Bico-de-Ouro-17-10; GN3: Pingo-de-Ouro-17-18; GN4: Bico-de-Oouro-17-19; GN5: Bico-de-Ouro-17-20; GN6: Bico-de-Ouro-17-44; GN7: Bico-de-Ouro-17-45; GN8: Bico-de-Ouro-17-46; GN9: Bico-de-Ouro-17-47; GN10: Pingo-de-Ouro-17-48; GN11: Bico-de-Ouro-17-72; G12: BRS Guariba; GN13: Bico-de-Ouro-17-82; GN14: Bico-de-Ouro-17-86; GN15: MNC01-631F-20-5; GN16: MNC00-595F-27; GN17: BRS Imponente; GN18: MNC06-895E-1; GN19: MNC09-981B-2; GN20: BRS Paraguaçu.

Techniques:

Journal: BMC research notes

Article Title: Preliminary characterization of IL32 in basal-like/triple negative compared to other types of breast cell lines and tissues.

doi: 10.1186/1756-0500-7-501

Figure Lengend Snippet: Figure 1 Gene expression profiles demonstrating IL32 levels in the GEO datasets used in the study. The plot represents the normalized IL32 gene expression levels observed for the Affymetrix 203826_s_at probeset in the (a) GDS2250 clinical samples (b) GDS1329 clinical samples (c) GSE34211 cell lines and (d) GSE12777 cell line datasets. The dashed lines are used to group the particular sample types. The normalized gene expression levels were averaged to demonstrate differences (i.e., mean) in IL32 levels between the various sample types. The mean and standard deviations values were also determined (using Excel).

Article Snippet: The IL32 antibody supplied by Novus Biologicals has been used to examine an assortment of different tissues and diseases as part of the Human Protein Atlas project [22].

Techniques: Gene Expression

Journal: BMC research notes

Article Title: Preliminary characterization of IL32 in basal-like/triple negative compared to other types of breast cell lines and tissues.

doi: 10.1186/1756-0500-7-501

Figure Lengend Snippet: Figure 2 Analysis showing overexpression of IL32 gene expression in MDA MB231 (TNBC) compared to MCF7 (receptor positive). (a) PCR analysis of IL32 transcript in MCF7 compared to MDA MB231. MRPL19 was used as the endogenous control gene (b) Western analysis of IL32 protein in MCF7, MDA MB231, Positive control protein and negative control. Actin gene was used as endogenous control.

Article Snippet: The IL32 antibody supplied by Novus Biologicals has been used to examine an assortment of different tissues and diseases as part of the Human Protein Atlas project [22].

Techniques: Over Expression, Gene Expression, Control, Western Blot, Positive Control, Negative Control

Journal: BMC research notes

Article Title: Preliminary characterization of IL32 in basal-like/triple negative compared to other types of breast cell lines and tissues.

doi: 10.1186/1756-0500-7-501

Figure Lengend Snippet: Figure 3 IHC analysis of IL32 levels in TMA. CD31 and IL32 protein expression was determined in various types of breast tissues. TNBC demonstrating (a) positive IL32 expression and (b) CD31 control expression. Non-TNBC demonstrating (c) positive IL32 expression and (d) CD31 control expression. Non-TNBC demonstrating (e) negative IL32 expression and (f) CD31 control expression. Invasive ductal or lobular carcinoma demonstrating (g) positive IL32 expression and (h) CD31 control expression. Bar = 50uM.

Article Snippet: The IL32 antibody supplied by Novus Biologicals has been used to examine an assortment of different tissues and diseases as part of the Human Protein Atlas project [22].

Techniques: Expressing, Control

Journal: Cell communication and signaling : CCS

Article Title: CHOP upregulation and dysregulation of the mature form of the SNAT2 amino acid transporter in the placentas from small for gestational age newborns.

doi: 10.1186/s12964-023-01352-5

Figure Lengend Snippet: Fig. 4 Levels of the placental mature form of the SNAT2 protein are reduced in SGA newborns. Placental mRNA levels of SNAT1 (SLC38A1) (A), SNAT2 (SLC38A2) (B), and LAT1 (SLC7A5) (C). Placental membrane cell lysate extracts were assayed via western blot analysis with antibodies against SNAT1 (D), SNAT2 (E), and LAT1 (F). Data (N = 10) are presented as the mean ± SEM. * p < 0.05 and *** p < 0.001 versus the AGA group. P-values determined by two-tailed unpaired Student’s t-test

Article Snippet: Immunoblotting was performed with antibodies against β-actin (Sigma, A5441), 4EBP1 (Cell Signalling, 9452), AKT (Cell Signalling, 9272), AMPKα (Cell Signalling, 2532), ATF4 (Santa Cruz Biotechnology, sc-200), ATF6 (Santa Cruz Biotechnology, sc-22799), BiP/GRP78 (Cell Signalling, 3183), CHOP (Cell Signalling, 2895), eIF2α (Cell Signalling, 9722), ERK1/2 (44/42 MAPK) (Cell Signalling, 9102), GADD34 (Cell Signalling, sc-46661), GAPDH (Millipore, MAB374), GRASP55 (Proteintech, 66,627–1-Ig), LAT1 (Cell Signalling, 5347), mTOR (Cell Signalling, 2972), Na–K-ATPase (Santa Cruz Biotechnology, sc-514614), NEDD4-L (Cell Signalling, sc-514954), phospho-4EBP1 Thr37/46 (Cell Signalling, 2855), phospho-AKT Ser473 (Cell Signalling, 9271), phospho-AMPKα Thr172 (Cell Signalling, 2531), phospho-ERK1/2 (44/42 MAPK) Thr202/Tyr204 (Cell Signalling, 9101), phospho-IRE Ser724 (Novus Biologicals, NB100-2323), phospho-mTOR Ser2448 (Santa Cruz Biotechnology, sc-101738), phospho-ribosomal protein S6 (Cell Signalling, 2211), ribosomal protein S6 (Cell Signalling, 2317), SNAT1 (Novus Biologicals, NBP-2–59311), SNAT2 (MBL, BMP081), and vinculin (Santa Cruz Biotechnology, sc-73614).

Techniques: Membrane, Western Blot, Two Tailed Test

Journal: Cell communication and signaling : CCS

Article Title: CHOP upregulation and dysregulation of the mature form of the SNAT2 amino acid transporter in the placentas from small for gestational age newborns.

doi: 10.1186/s12964-023-01352-5

Figure Lengend Snippet: Fig. 5 GADD34 inhibition by guanabenz attenuates the reduction in mTORC1 activity and the increase in CHOP levels caused by ER stress in the human placental cell line BeWo. BeWo cells were stimulated with 0.1 μg/ml of tunicamycin (TM) either in the presence or absence of 5 μM guanabenz (GB) for 24 h and the protein levels of total and phosphorylated RPS6 (A), CHOP (B), SNAT1 (C), and SNAT2 (D) were assessed. Data (N = 3) are presented as the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 versus the AGA group. P-values determined by two-tailed unpaired Student’s t-test

Article Snippet: Immunoblotting was performed with antibodies against β-actin (Sigma, A5441), 4EBP1 (Cell Signalling, 9452), AKT (Cell Signalling, 9272), AMPKα (Cell Signalling, 2532), ATF4 (Santa Cruz Biotechnology, sc-200), ATF6 (Santa Cruz Biotechnology, sc-22799), BiP/GRP78 (Cell Signalling, 3183), CHOP (Cell Signalling, 2895), eIF2α (Cell Signalling, 9722), ERK1/2 (44/42 MAPK) (Cell Signalling, 9102), GADD34 (Cell Signalling, sc-46661), GAPDH (Millipore, MAB374), GRASP55 (Proteintech, 66,627–1-Ig), LAT1 (Cell Signalling, 5347), mTOR (Cell Signalling, 2972), Na–K-ATPase (Santa Cruz Biotechnology, sc-514614), NEDD4-L (Cell Signalling, sc-514954), phospho-4EBP1 Thr37/46 (Cell Signalling, 2855), phospho-AKT Ser473 (Cell Signalling, 9271), phospho-AMPKα Thr172 (Cell Signalling, 2531), phospho-ERK1/2 (44/42 MAPK) Thr202/Tyr204 (Cell Signalling, 9101), phospho-IRE Ser724 (Novus Biologicals, NB100-2323), phospho-mTOR Ser2448 (Santa Cruz Biotechnology, sc-101738), phospho-ribosomal protein S6 (Cell Signalling, 2211), ribosomal protein S6 (Cell Signalling, 2317), SNAT1 (Novus Biologicals, NBP-2–59311), SNAT2 (MBL, BMP081), and vinculin (Santa Cruz Biotechnology, sc-73614).

Techniques: Inhibition, Activity Assay, Two Tailed Test

Journal: The Journal of investigative dermatology

Article Title: IL-32 Supports the Survival of Malignant T Cells in Cutaneous T-cell Lymphoma.

doi: 10.1016/j.jid.2022.01.009

Figure Lengend Snippet: Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) IL-32b supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.

Article Snippet: A total of 300,000e1,000,000 cells in 200 ml per well were cultured in round-bottom 96-well plates in the presence or absence of IL-2 (25 IU/ml, National Cancer Institute, Bethesda, MD), IL-32a (25 ng/ml; number 3040-IL-050, R&D Systems), IL-32b (25 ng/ml; number 6769-IL-025, R&D Systems), or IL-32g (25 ng/ml; number 4690-IL-025/CF, R&D Systems).

Techniques: High Throughput Screening Assay, Sequencing